MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-06-2024
Endo International plc Depreciation & Amortization 2011-2026 | ENDP
Annual Depreciation & Amortization Endo International plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 306 M | 392 M | 457 M | 519 M | 69 M | 101 M | 210 M | 107 M | 59.9 M | 51.1 M | 256 M | 286 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 519 M | 51.1 M | 234 M |
Quarterly Depreciation & Amortization Endo International plc
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 77.9 M | - | 302 M | 206 M | 106 M | - | 350 M | 238 M | 118 M | - | 391 M | 264 M | 142 M | - | 468 M | 321 M | 163 M | - | 557 M | 380 M | 192 M | - | 743 M | 500 M | 287 M | - | 716 M | 477 M | 236 M | - | 382 M | 249 M | 120 M | 70.9 M | 233 M | 153 M | 74.6 M | 26.5 M | 196 M | 135 M | 66.8 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 743 M | 26.5 M | 271 M |
Depreciation & Amortization of other stocks in the Drug manufacturers industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
311 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
8.75 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
6.4 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
102 K | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.48 M | - | 0.86 % | $ 117 M | USA |
 |
Perrigo Company plc
PRGO
|
338 M | $ 9.69 | 0.52 % | $ 1.34 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
646 K | - | -39.89 % | $ 27.7 M | USA |
 |
Rockwell Medical
RMTI
|
1.44 M | $ 1.04 | 0.97 % | $ 24.3 M | USA |
 |
Catalent
CTLT
|
489 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
4.47 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
2.68 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
31 K | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
125 M | $ 8.21 | 2.43 % | $ 420 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
138 K | $ 2.28 | -2.56 % | $ 2.83 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
4.9 M | $ 3.35 | 7.03 % | $ 47.1 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.04 M | - | - | $ 193 M |  Canada |
 |
Bausch Health Companies
BHC
|
1.26 B | $ 5.08 | 1.8 % | $ 1.85 B | Canada |
 |
PetIQ
PETQ
|
44.5 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
402 K | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
116 K | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
4.72 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
268 K | $ 2.29 | - | $ 309 M | USA |
 |
Pacira BioSciences
PCRX
|
78.8 M | $ 23.49 | 1.25 % | $ 1.09 B | USA |
 |
Evolus
EOLS
|
7.51 M | $ 4.37 | -1.35 % | $ 282 M | USA |
 |
Radius Health
RDUS
|
1.16 M | - | - | $ 1.42 B | USA |
 |
Solid Biosciences
SLDB
|
1.64 M | $ 7.23 | 8.23 % | $ 633 M | USA |
 |
Relmada Therapeutics
RLMD
|
1.26 K | $ 6.66 | 9.18 % | $ 263 M | USA |
 |
Tilray
TLRY
|
35.7 M | $ 6.94 | 4.2 % | $ 4.29 B | Canada |
 |
SCYNEXIS
SCYX
|
580 K | $ 0.88 | -2.13 % | $ 43.9 M | USA |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
Viatris
VTRS
|
2.74 B | $ 13.5 | 1.05 % | $ 16.2 B | USA |
 |
China Pharma Holdings
CPHI
|
2.62 M | $ 0.6 | 2.41 % | $ 10.5 M |  China |
 |
cbdMD
YCBD
|
452 K | $ 0.81 | 4.7 % | $ 3.49 M | USA |
 |
Assertio Holdings
ASRT
|
30 M | $ 18.57 | 12.48 % | $ 119 M | USA |
 |
Lannett Company
LCI
|
34.3 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
13.6 M | $ 2.44 | 1.24 % | $ 321 M | USA |
 |
Canopy Growth Corporation
CGC
|
21.5 M | $ 0.97 | 1.5 % | $ 104 M | Canada |
 |
Harrow Health
HROW
|
1.32 M | $ 36.35 | 3.27 % | $ 1.34 B | USA |
 |
TherapeuticsMD
TXMD
|
922 K | $ 2.29 | - | $ 23.9 M | USA |
 |
Recro Pharma
REPH
|
8.22 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
442 K | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
219 K | - | - | $ 55.5 M | USA |